A new anti-malaria vaccine called Mosquirix was recently approved by the European drugs regulators. Projected as the solution to malaria, the mosquito-borne disease that kills one child every 30 seconds, about 3,000 children everyday worldwide and over 300,000 Nigerians every year, it is already being recommended as safe and effective to use on babies in Africa. If the trials prove to be successful, and the economics work, this will be a major breakthrough in the fight against a scourge that is without any doubts the biggest killer-disease on the continent. The office of the United Nations Secretary-General’s Special Envoy for Malaria, Ray Chambers’, once drew attention to the fact that more than 90 per cent of the world’s malaria deaths occur in sub-Saharan Africa. That then explains why we believe that this vaccine could not have come at a better time, even though this is just the beginning of what could also be a long road before it would become readily available to the end-users.